The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?
Clinical Pharmacology in Drug Development · 2026-03 · 15 (3)
DOI: 10.1002/cpdd.70046 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.03.2026. Verfasst von Michael J Fossler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology in Drug Development, Ashburn, VA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Clinical Pharmacology in Drug Development, Ashburn, VA, USA.
- Strategic Consulting, Cytel, Waltham, MA, USA.
- Mammoth Pre-Clinical Consulting, Placitas, NM, USA.
- Modeling and Simulation, Resero Analytics, Indianapolis, IN, USA.
Zitieren
APA
Fossler, M. J., & Garner, C. E. (2026). The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?. Clinical Pharmacology in Drug Development, 15(3). https://doi.org/10.1002/cpdd.70046
Vancouver
Fossler MJ, Garner CE. The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?. Clinical Pharmacology in Drug Development. 2026;15(3). doi:10.1002/cpdd.70046
BibTeX
@article{Fossler2026,
author = {Fossler, Michael J and Garner, C Edwin},
title = {The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cpdd.70046}
}
EUVIMED